Clinical Trials Browser

Phase 2/3 × OTHER × Rivaroxaban × Clear all

NCT05920343 2025-07-10

PREVENT-GU

Phase 2/3 Recruiting

Classical hematologyGenitourinary

Urogenital Neoplasms, Urologic Neoplasms, Venous Thromboembolism